Pfizer’s Q1FY27 performance was in line with our expectations. Revenue growth of 8.3% YoY is likely to be supported by traction in Zavicefta and Eliquis. In Dec’25, Pfizer out-licensed four brands — Corex Dx and Corex LS, Dolonex and Neksium — to Cipla.